Related by context. All words. (Click for frequent words.) 70 PLCO 68 ACRIN 67 BCIRG 66 Digital Mammographic Imaging 66 Prostate Lung Colorectal 65 Screening Trial DMIST 65 ERSPC 64 Screening Trial 63 DMIST 63 Ovarian Cancer Screening 63 CALGB 63 RTOG 62 HPTN 62 NSABP 62 Prostate Cancer Prevention 62 CARE HF 62 Early Lung Cancer 62 EchoCRT 62 Intervention Trial GAIT 62 multicenter randomized clinical 62 Ovarian PLCO Cancer 61 EORTC 61 LUX Lung 61 SCD HeFT 61 Trial PCPT 61 prospective multicenter 61 BRIM3 61 ENDEAVOR IV 61 multicenter trials 61 Phase Ib clinical 61 ONTARGET 61 ToGA 61 PRESEPT 61 AVADO 60 LUMINATE 60 CHAMPION PCI 60 HORIZONS AMI trial 60 RE LY 60 ENESTnd 60 phase IIb clinical 60 Lung Cancer Screening 60 ExTRACT TIMI 60 ACOSOG Z# 60 riociguat 60 European Randomized Study 60 ISEL 60 SWOG 60 ACUITY trial 60 Multicenter Automatic Defibrillator Implantation 60 IMPROVE HF 60 Trial NLST 60 Gynecologic Oncology Group 60 multicenter randomized controlled 59 Stenting Trial CREST 59 MADIT II 59 confirmatory clinical 59 NCIC CTG 59 NCCTG 59 olaparib 59 figitumumab 59 Women Ischemia Syndrome 59 Phase Ib II 59 HeFT 59 substudy 59 multicenter Phase 59 EVEREST II 59 RE LY ® 59 Azedra 59 subgroup analyzes 59 randomized Phase III 59 BARI 2D 59 PERSEUS 59 Atherosclerosis MESA 59 BRIM2 58 multicenter clinical 58 clinical trial 58 PFO migraine 58 AVERROES 58 PROactive study 58 Phase III VISTA 58 prospective longitudinal 58 NO# [002] 58 Carotid Revascularization Endarterectomy vs. 58 EDRN 58 multicenter Phase II 58 phase IIa clinical 58 ASPIRE HIGHER 58 multicenter study 58 CT Colonography 58 phase IIb trial 58 placebo controlled clinical 58 neoadjuvant treatment 58 pivotal bioequivalence 58 STRIDE PD 58 OLYMPIA registry 58 ECASS 58 rALLy trial 58 APPRAISE 58 placebo controlled Phase 57 axitinib 57 Prostate AdenoCarcinoma Treatment 57 EUS FNA 57 Hepatocellular Carcinoma HCC 57 afatinib 57 placebo controlled Phase III 57 Edge STudy 57 NABTT 57 DAPT Study 57 iPrEx study 57 Meta analyzes 57 randomized controlled clinical 57 AIR2 Trial 57 Clinical Antipsychotic Trials 57 STICH trial 57 REALITY Trial 57 pharmacokinetic PK 57 HCV SPRINT 57 VADT 57 Dr. Kandzari 57 pertuzumab 57 AIM HIGH 57 ALLHAT 57 Group RTOG 57 Multicenter AIDS 57 ELACYT 57 Patient Registry 57 observational cohort study 57 neratinib 57 assessing T DM1 57 MADIT CRT 57 HYVET 57 PSMA ADC 57 alvespimycin 57 ONTARGET R 57 IMPROVE IT 57 HER2 positive metastatic breast 57 blinded randomized controlled 57 prospective multicentre 57 recurrent glioblastoma multiforme 57 NICE SUGAR 57 PROSTVAC TM 57 phase Ib 57 PLCO trial 56 Radiation Therapy Oncology 56 Delcath Phase III 56 Aggressive Reduction 56 EMPHASIS HF trial 56 REACH Registry 56 p# biomarker 56 randomized multicenter trial 56 CURRENT OASIS 7 56 HuMax EGFr 56 CALGB # [002] 56 LibiGel Phase III 56 selenium supplementation 56 phase IIIb 56 FDG PET 56 randomized controlled clinical trials 56 retrospective cohort 56 sentinel lymph node biopsy 56 farletuzumab 56 depsipeptide 56 YONDELIS 56 iPrEx 56 SUCCEED trial 56 Advaxis Phase 56 ENDEAVOR III 56 GRAVITAS trial 56 randomized blinded 56 Framingham Offspring Study 56 AVAiL 56 prostate cancer CaP 56 MADIT 56 Tyrima 56 CTRC AACR San Antonio 56 chemoradiotherapy 56 WHEL 56 HF ACTION 56 LungAlert TM 56 number NCT# ClinicalTrials.gov 56 CAPRISA 56 phase IIb 56 Diabetes ACCORD 56 dose escalation Phase 56 multicenter prospective 56 multicentre randomized 56 lorvotuzumab mertansine 56 IMC #B 56 randomized Phase IIb 56 prospective randomized controlled 56 neoadjuvant therapy 56 dose escalation clinical 56 Wisconsin Sleep Cohort 56 Gynecological Cancer 56 SYNTAX trial 56 prospectively defined 56 NP2 Enkephalin 56 PROLARIS 56 clinical pharmacology studies 56 multicenter phase 56 ADVANCE PD 56 TAXUS IV 56 BioNumerik 56 TrialNet 56 subanalysis 56 CAMMS# 56 prospective nonrandomized 56 TACI Ig 56 NEVO RES 56 CHARISMA trial 55 ABCSG 55 ADAGIO study 55 HGPIN 55 randomized multicenter 55 IASLC 55 enzastaurin 55 Subgroup analysis 55 randomized trials 55 trials RCTs 55 randomized clinical 55 Cholesterol Levels SPARCL 55 oral ridaforolimus 55 SYMMETRY trial 55 Phase 2a trial 55 APEX PD 55 phase IIa 55 Truvada tablets 55 metastatic colorectal 55 TG MV 55 immatics 55 RE LY trial 55 multicentre 55 NSABP B 55 NCCTG N# 55 VITAL Trial 55 Aplidin 55 APEX AMI trial 55 multicenter placebo controlled 55 relapsed MM 55 multicentre study 55 DFCI 55 tremelimumab 55 prospective observational cohort 55 immunohistochemical 55 tesmilifene 55 Multiethnic Study 55 CALGB # [001] 55 Health Initiative Observational 55 LungSign TM 55 oral FTY# 55 viral kinetic 55 rALLy clinical trial 55 Health Initiative WHI 55 GAP #B# 55 cediranib 55 Study ADCS 55 Phase 1a clinical 55 Phase III randomized 55 crizotinib PF # 55 prospective observational studies 55 phase IIb study 55 Phase Ib study 55 pancreatic adenocarcinoma 55 SPIRIT FIRST 55 Celecoxib APC trial 55 National Oncologic PET 55 SPIRIT IV 55 Phase IIb III 55 ABSORB trial 55 ASCEND HF 55 Autism Consortium 55 registrational 55 ENDEAVOR clinical 55 ImmuKnow assay 55 CR# vcMMAE 55 FDG-PET/CT 55 SABCS 55 ongoing Phase IIIb 55 Lung Screening 55 StemEx R 55 longitudinal cohort study 55 Phase III TRIST 55 ACTIVE W 55 ataluren 55 Cloretazine 55 neoadjuvant 55 CLARITY study 55 registrational Phase 55 ICON7 55 entinostat 55 MGd 55 CyberKnife radiosurgery 55 ductal carcinomas 55 EOquin TM 55 Cancer Prevention ATBC 55 ConclusionThis 55 NeuroStar TMS Therapy 55 recurrent metastatic 55 Multi Ethnic Study 55 PARTNER Trial 55 clinicaltrials 55 Cotara 55 colorectal cancer CRC 55 ARDIS 55 Chicago Multidisciplinary Symposium 55 observational cohort 54 double blinded randomized 54 PREVENT IV 54 IMA# 54 ARBITER 6 54 CARDIA study 54 SEER database 54 radiolabeled TM# 54 sentinel node biopsy 54 ZACTIMA 54 PEARL SC 54 Phase IIB 54 chemoprevention trials 54 Evaluation WISE 54 Phase #b/#a 54 multicentre prospective 54 preoperative MRI 54 phase III ACCLAIM 54 Glucosamine chondroitin Arthritis 54 Curaxin 54 PreCISe 54 Phase III psoriasis 54 Renal Cell Carcinoma RCC 54 prospectively randomized 54 recurrent glioma 54 TRO# 54 HCV RESPOND 2 54 randomized clinical trials 54 ALSYMPCA 54 Afatinib 54 flurpiridaz F 54 MelaFind pivotal 54 #F FDG PET 54 Avastin adjuvant 54 Prostate Cancer ERSPC 54 WTCCC 54 Cloretazine ® 54 Cardiotoxicity 54 PhG alpha 1 54 unblinded 54 Cohort Study MACS 54 CIBMTR 54 European Sepsis Trial 54 Exherin TM 54 Phase III randomized controlled 54 Corus CAD 54 nonrandomized 54 CaPSURE 54 Immunohistochemistry 54 medically inoperable 54 GAMMAGARD 54 clinically localized prostate 54 PRIMO CABG 54 IIa clinical 54 ClinicalTrials.gov 54 Intervention Effectiveness 54 Alzheimer Disease Neuroimaging Initiative 54 preoperative chemotherapy 54 Registry NOPR 54 Lp PLA 2 54 ixabepilone 54 elacytarabine 54 SPARCL 54 Pertuzumab 54 CTSAs 54 Dr. Fehlings 54 prospective observational 54 Tesmilifene 54 Vasogen Celacade 54 Research Network EDRN 54 UKPDS 54 Septin9 54 Cardiac Allograft Rejection 54 liver metastases 54 Velcade bortezomib 54 oral deforolimus 54 STEP BD 54 pharmacodynamic effects 54 Intervention Effectiveness CATIE 54 AZILECT ® 54 brivaracetam 54 IMC A# 54 fosbretabulin 54 Lancet Oncology journal 54 sunitinib malate 54 Wactawski Wende 54 Onrigin 54 CYPHER Stent 54 Dubbo Osteoporosis Epidemiology 54 ACCORD Eye 54 Consortium ICGC 54 NOX E# 54 differentiated thyroid 54 Prospective Randomized 54 HORIZONS AMI 54 oral Xeloda 54 KRAS status 54 peritoneal cancer 54 Insulin Resistance Atherosclerosis 54 National Surgical Adjuvant 54 neoadjuvant chemotherapy 54 PD2i ® 54 RECIST Response Evaluation Criteria 54 genitourinary cancers 54 PRIMO CABG2 54 NATRECOR ® 54 spiral computed tomography 54 GVAX Pancreas Vaccine 54 Phase 2b study 54 Phase Ib 54 percutaneous cryoablation 54 GISSI 54 atherothrombotic disease 54 Elocalcitol 54 PRECiSE 54 liver transplant recipients 54 PCI ExTRACT TIMI 53 Phase III metastatic melanoma 53 Phase IIIb clinical 53 huC# DM4 53 Sipuleucel T 53 AE# vaccine 53 ILLUMINATE 53 QOPI 53 MERLIN TIMI 53 blinded randomized 53 Ophena 53 histologic diagnosis 53 randomized multicentre 53 CUSTOM II 53 ONCONASE R 53 CardioFit 53 INTERPHONE 53 Val HeFT 53 SPIRIT III 53 PRoFESS 53 tumor histology 53 DF HCC 53 DSMB 53 PIX# [002] 53 adecatumumab 53 BRAF mutated 53 galiximab 53 FDA Investigational Device 53 Trandolapril 53 Proellex TM 53 REGARDS 53 IMPACT IMmunotherapy 53 trastuzumab emtansine T DM1 53 Dialysis Outcomes 53 Curaxin CBLC# 53 HER2 positive cancers 53 randomized discontinuation trial 53 VNP#M 53 Raloxifene STAR 53 NATRECOR R 53 CLIRS 53 PRESEPT Study 53 PROSTVAC ® 53 Immune Tolerance Network 53 multicenter randomized 53 Phase #/#a trial 53 CoFactor 53 multicenter randomized Phase III 53 placebo controlled randomized 53 PEG SN# 53 randomized controlled Phase 53 Xelox 53 MEND CABG 53 randomized blinded placebo 53 Sentinel node biopsy 53 EBUS FNA 53 Angiolix 53 mertansine 53 castration resistant prostate cancer 53 HGS# 53 DermaVir Patch 53 methodologically rigorous 53 prospective multicenter study 53 RIO Lipids 53 Michigan Comprehensive Cancer 53 preclinically 53 BHGI 53 prospective randomized placebo 53 pharmacokinetic pharmacodynamic 53 CLL8 53 dose escalation trial 53 Heart Failure Trial 53 Swedish Mammography Cohort 53 retrospective cohort study 53 Sorafenib HCC Assessment 53 ASTEROID 53 randomized Phase 2b 53 prostate carcinogenesis 53 INTERHEART study 53 Motesanib 53 recurrent malignant glioma 53 CT colonography CTC 53 cardio renal 53 indibulin 53 advanced metastatic prostate 53 Phase #/#a 53 carotid artery stenting 53 adjuvant radiotherapy 53 cortical stimulation 53 Phase #b/#a clinical 53 Radiology Imaging Network ACRIN 53 BRCA mutation carriers 53 EURIDIS 53 Novartis Zometa 53 Enzastaurin 53 GRAVITAS 53 vorinostat 53 pharmacokinetic PK study 53 Phase 1b clinical trials 53 COSIRA trial 53 Glucosamine Chondroitin Arthritis 53 Electronic Brachytherapy 53 CALERIE 53 metastatic RCC 53 Multiple logistic regression 53 virtual colonography 53 tanespimycin 53 mg/m2 cohort 53 Quinamed 53 multicenter 53 Cochrane Systematic Review 53 ALTTO 53 COR Analyzer 53 Phase IIIb study 53 landmark ATHENA 53 MAGE A3 53 OvaRex MAb 53 Endeavor Resolute DES 53 Symadex 53 prostate cancer PCa 53 Alpha Tocopherol Beta Carotene 53 Survivorship Program 53 letrozole 53 multicentric 53 Multicentre 53 adjuvant therapy 53 invasive lobular carcinoma 53 Gynecologic Cancer Society 53 NCT# ClinicalTrials.gov 53 DNA methylation biomarker 53 PCPT 53 BOLDER II 53 Pregnancy Registry 52 OMP #M# 52 BLP# Liposome Vaccine 52 Cervista HPV HR 52 OncoVex 52 Neuradiab TM 52 Phase 1b trial 52 randomized controlled trial 52 AA Amyloidosis 52 CombAT 52 Spine Patient Outcomes 52 immunochemical fecal occult 52 ADMIRE HF 52 dose escalation 52 chromium supplementation 52 CHAMPION PLATFORM 52 malignant pleural mesothelioma 52 ENGAGE AF TIMI 52 IMGN# 52 Multivariate logistic regression 52 TNFerade TM 52 breast irradiation 52 NCIC Clinical Trials 52 SIMPADICO 52 skin sterol 52 CAPRIE 52 Hexvix 52 glufosfamide 52 AVOREN 52 IL# PE#QQR 52 renal tumors 52 ON #.Na 52 HIVNET 52 F FDG PET 52 OPT CHF 52 adjuvant chemotherapy 52 CUSTOM III 52 lorcaserin Phase 52 Nutrition EPIC 52 TRITON TIMI 52 genomewide association study 52 endometrial carcinoma 52 pelvic malignancies 52 Asthma Intervention 52 Phase III clinical 52 PANVAC VF 52 preclinical efficacy 52 pain palliation 52 Tavocept 52 pancreatic islet cell 52 ganetespib 52 prostate cancer CRPC 52 thoracoscopic lobectomy 52 Marrow Transplant Research 52 evaluating Nexavar 52 SLNB 52 Aflibercept 52 MOZOBIL 52 ACCORD Lipid 52 PET scanning 52 metastatic HRPC 52 miRview TM mets 52 hepatic arterial 52 Apixaban 52 TARGIT 52 bone metastasis 52 recurrent ovarian cancer 52 Clinical Outcomes Utilizing Revascularization 52 Bowel Project NSABP 52 TMC# C# 52 Subgroup analyzes 52 lintuzumab 52 Randomized trials 52 Phase Ia 52 deforolimus 52 IRX 2 52 radiotherapy SBRT 52 clinical trials 52 vandetanib 52 SYNTAX 52 Randomized clinical trials 52 GELA 52 antitumor effect 52 Automated Breast Ultrasound 52 sipuleucel T 52 Colposcopy 52 placebo controlled dose escalation 52 florbetaben 52 metastatic liver 52 dose escalation study 52 talabostat 52 Trofex 52 Getzenberg 52 cardiac computed tomography 52 Proxinium TM 52 Eric Van Cutsem 52 TEMSO 52 Phase Ib IIa clinical 52 Stereotactic Body Radiation Therapy 52 renal cell carcinomas 52 folate supplementation 52 Cancer Genome 52 TAXUS V 52 OVATURE trial 52 WHIMS 52 UPCI 52 phase III SIMPADICO 52 CATIE AD 52 Cell Signalling 52 abiraterone acetate 52 axillary dissection 52 MIST II 52 VESTASYNC 52 genomic profiling 52 UEGW 52 fine needle aspiration 52 Vandetanib 52 unblinding 52 Rheos System 52 RESOLUTE clinical 52 Phase 1b 52 HRPC 52 Epidemiologic studies 52 BRCA testing 52 prospective randomized multicenter 52 Multicenter 52 Neuradiab 52 TRA 2P 52 National Emphysema Treatment 52 Alzheimer Disease Cooperative 52 pediatric malignancies 52 functional neuroimaging 52 ELOXATIN 52 AP# [003] 52 therapeutic monoclonal antibody 52 Randomized controlled 52 CROI 52 Dr. Pingpank 52 Lung Cancer IASLC 52 Safinamide 52 recurrent ovarian 52 MSKCC 52 QTinno 52 vismodegib 52 Trophos 52 COPERNICUS 52 arzoxifene 52 Cloretazine R 52 ASSERT trial 52 ExCell study 52 PET CT scanning 52 double blinded placebo 52 clinicopathologic 52 Hydroxyurea 52 Phase #/#a clinical 52 pCR 52 randomized controlled trials RCTs 52 Response Evaluation Criteria 52 thorough QT 52 Pre RELAX AHF 52 glatiramer acetate 52 MTWA testing 52 COU AA 52 ASSERT 52 ADXS# 52 Abiraterone 52 CT Colonography Trial 52 prognostic variables 52 XELOX 52 Phase IIA 52 BRAF inhibitor 52 Psycho Oncology 52 observational studies 52 cerebral microbleeds 52 HPCGG 52 Neoadjuvant 52 BioMarck 52 YONDELIS R 52 nab paclitaxel 52 NCI Cancer 52 trastuzumab DM1 52 ThermoDox ® clinical 52 Myocet 52 micrometastases 52 ICGC 52 elotuzumab 51 CA4P 51 Phase 2b monotherapy 51 trastuzumab DM1 T DM1 51 randomized controlled 51 HuLuc# 51 Group ECOG 51 undergone radical prostatectomy 51 ductal adenocarcinoma 51 TNM staging 51 VEITHsymposium 51 randomized crossover 51 Folfox 51 Tom Misteli 51 lymphadenectomy 51 preoperative staging 51 MAGE A3 ASCI 51 Diabetes Interventions 51 receptor tyrosine kinase inhibitor 51 CRLX# 51 mammographic density 51 International Verapamil SR 51 DXA scan 51 Dose escalation 51 PD2i R 51 transrectal ultrasound guided 51 lung metastasis 51 chronic myocardial ischemia 51 placebo controlled trials 51 Lymph node 51 CYT# potent vascular disrupting 51 blinded randomized placebo controlled 51 CLARITY TIMI 51 RRMS patients 51 Oncimmune 51 dbGaP 51 Xanafide 51 brain metastases 51 Faslodex 51 relapsing remitting MS RRMS 51 abiraterone 51 AEG# 51 ASA# 51 masked placebo controlled 51 Amrubicin 51 PRECISE trial 51 Diamyd r vaccine 51 advanced adenomas 51 recurrent GBM 51 carcinoid 51 PCAW 51 anti angiogenic therapy 51 DASISION 51 OvaRex ® MAb 51 metaanalysis 51 Dr. Ayalew Tefferi 51 Surgical resection 51 chemoradiation therapy 51 phase Ib clinical 51 rectal cancers 51 obatoclax 51 #I TM# 51 Aplidin R 51 hereditary medullary thyroid 51 Phase IIIb 51 Zarnestra 51 transcranial Doppler ultrasound 51 bevacizumab Avastin ® 51 PERSEUS clinical program 51 ZD# [001] 51 Bowel Project 51 EQUIP OB 51 Normative Aging Study 51 lipid lowering therapy 51 PSA screening 51 Dr. Roehrborn 51 sorafenib Nexavar 51 REVIVE Diabetes 51 solithromycin 51 Randomized Evaluation 51 ABSORB clinical 51 LHRH receptor positive 51 ASCO GI 51 oral PrEP 51 NovoTTF 51 Thoracic Oncology 51 BR.# 51 electron beam computed tomography 51 MOTIVATE 51 thromboembolic disease 51 axillary lymph nodes 51 KRAS gene mutations 51 liver metastasis 51 Genitourinary Cancers Symposium 51 Phase III multicenter 51 Intervention Trial 51 adjuvant radiation 51 gastrointestinal GI cancers 51 ECTRIMS 51 dasatinib 51 multimodality therapy 51 pelvic lymphadenectomy 51 APTIVUS 51 longitudinal observational study 51 IIa trial 51 ASCO GU 51 cervical carcinoma 51 TroVax 51 Tanespimycin 51 clevidipine 51 teriflunomide 51 lymph node metastases 51 Accelerated Partial Breast Irradiation 51 HSCT 51 recurrent glioblastoma multiforme GBM 51 CEQ# 51 thyroid nodules 51 axillary node 51 Fondazione IRCCS Istituto Nazionale 51 strontium ranelate 51 ProSavin 51 contralateral breast 51 MEND CABG II 51 recurrent prostate cancer 51 pharmacokinetic characteristics 51 randomized controlled trials 51 clinico pathological 51 Teriflunomide 51 biomarker identification 51 keloid scarring 51 registrational trial 51 Breast Cancer Detection 51 IMPACT DCM clinical 51 Netherlands Cohort Study 51 Urocortin 2 51 Interventional Radiology SIR 51 NSTE ACS 51 Phase Ib clinical trials 51 Gastric Cancer 51 midstage clinical 51 adjuvant tamoxifen 51 ORACLE MS 51 RCW Breast Cancer 51 Phase 2b trial 51 aflibercept 51 Atherosclerosis Risk 51 HPV genotyping 51 RhuDex 51 QUASAR validation study 51 Prostate Specific Antigen PSA 51 flavopiridol 51 OncoVEX GM CSF 51 AREDS 51 nodal metastasis 51 epithelial ovarian 51 GYTS 51 EFAPROXYN 51 MIVI TRUST 51 Dr. Beilharz 51 EUROCARE 51 dose escalation phase 51 RECORD1 51 crizotinib 51 endometrial hyperplasia 51 nonmetastatic 51 ovarian endometrial 51 ximelagatran 51 papillary renal cell carcinoma 51 lymphatic mapping 51 NINDS 51 mapatumumab 51 Zivadinov 51 Phase IIb trial 51 CONQUER OB 51 Phase 2a clinical 51 SNT MC# 51 Degarelix 51 Biomarkers Consortium 51 hepatocellular carcinoma 51 postoperative chemotherapy 51 adenoma recurrence 51 KLRI 51 PROMACTA 51 adjuvant endocrine therapy 51 multicenter randomized placebo controlled 51 CLIRS trial 51 velafermin 51 NHANES III 51 Dr. Claudia Henschke 51 Arteriosclerosis Thrombosis 51 bevacizumab Avastin 51 ongoing Phase 1b 51 Neck Cancer 51 OSUCCC 51 clinicopathological 51 trastuzumab Herceptin 51 Bayer HealthCare Onyx Pharmaceuticals 51 Acute Myocardial Infarction 51 MIS# 51 diagnostic biomarker 51 Phase 2b kidney transplant 51 Solazed 51 dosing cohort 51 TAXUS ARRIVE 51 BrachySil TM 51 INCB# [001] 51 colorectal neoplasia 51 antibody MAb 51 BAY #-# 51 Fablyn 51 SANTE 51 HDL Selective Delipidation 51 colonoscopic 51 Flexi Scope 51 chlamydial infection 51 Group NCCTG 51 temsirolimus 51 SIR Spheres microspheres 51 imetelstat 51 CIN2 + 51 deCODE ProstateCancer TM 51 Vidofludimus 51 DAPT 51 Prostate Cancer Clinical Trial 51 predictive biomarkers 51 lymph node dissection 51 scintigraphic 51 heavily pretreated 51 standard chemotherapy regimen 51 prostate cancer mCRPC 51 kinase profiling 51 ThinPrep Imaging System 51 OncotypeDX 51 Consortium MMRC 51 cytological 51 Zevalin consolidation 50 metastatic hormone refractory 50 ADNI 50 ID NCT# 50 meta analysis 50 PRECISE 50 abstracts summarizing 50 Ovarian Cancer Coalition NOCC 50 brivanib 50 FOLOTYN ® 50 Vascugel ® 50 HER2 overexpression 50 Solid Tumors 50 IMPACT DCM 50 Phase IIa trial 50 endoscopic ultrasound 50 Dr. Cliby 50 KRAS mutation 50 Phase III ThermoDox 50 Refractory Angina 50 Colon polyps 50 PTK ZK 50 nonsmall cell lung cancer 50 Gastrointestinal Oncology 50 tumor subtypes 50 GVAX